检索范围:
排序: 展示方式:
null
《医学前沿(英文)》 2015年 第9卷 第4期 页码 468-477 doi: 10.1007/s11684-015-0419-6
Mature T-cell lymphoid malignancies comprise a group of heterogeneous diseases that vary in clinicopathological features, biological behavior, treatment response, and prognosis. Bone marrow (BM) infiltration is more commonly present in mature T-cell lymphoid malignancies compared with their B-cell counterparts and hence important for differential diagnosis. In this study, clinical characteristics and prognostic factors were analyzed in 225 patients with mature T-cell lymphoid malignancies treated in a single institution. These included 29 cases of T-cell lymphoproliferative disorders (T-LPD, all with BM infiltration) and 196 cases of T-/natural-killer-cell lymphoma (T/NKCL, 56 with BM infiltration and 140 without BM infiltration). The estimated 5-year overall survival (OS) rates of T-LPD and T/NKCL were 96.6% and 37.3%, respectively. T-LPD patients were less likely to exhibit poor performance status, advanced disease stage, presence of B symptoms, or abnormal level of serum β-2 microglobulin. With similar pathological characteristics, T/NKCL patients with BM infiltration showed significantly lower response rates and shorter OS than those without BM infiltration (P = 0.0264 and P<0.0001, respectively). Multivariate analysis indicated that poor performance status, advanced disease stage, elevated serum lactate dehydrogenase level, and BM involvement were independent unfavorable prognostic factors. The Glasgow Prognostic Score may be more efficient than the International Prognostic Index in predicting disease outcome in T/NKCL. In conclusion, clinical characteristics may be useful in more effectively stratifying patients with mature T-cell lymphoid malignancies.
关键词: mature T-cell lymphoid malignancies clonal T-cell population bone marrow infiltration prognostic factors
CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies
《医学前沿(英文)》 2021年 第15卷 第6期 页码 783-804 doi: 10.1007/s11684-021-0904-z
Ling Wang, Lining Wang, Xing Fan, Wei Tang, Jiong Hu
《医学前沿(英文)》 2021年 第15卷 第1期 页码 108-115 doi: 10.1007/s11684-019-0730-8
关键词: post-transplantation cyclophosphamide allogeneic hematopoietic stem cell transplantation lymphoid malignancies
Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia
《医学前沿(英文)》 2022年 第16卷 第3期 页码 442-458 doi: 10.1007/s11684-021-0877-y
关键词: T-cell acute lymphoblastic leukemia HDAC inhibitor chidamide NOTCH1 MYC ubiquitination
Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia
null
《医学前沿(英文)》 2012年 第6卷 第4期 页码 416-420 doi: 10.1007/s11684-012-0224-4
Acute lymphoblastic leukemia includes T-cell acute lymphoblastic leukemia (T-ALL) and B-cell acute lymphoblastic leukemia (B-ALL). In children, T-ALL usually has a worse prognosis than B-ALL, although childhood T-ALL prognoses have improved remarkably. The varying outcomes among T-ALL cases suggest that an unrecognized biological heterogeneity may contribute to chemo-resistance. Deep exploration of T-lymphocyte development in recent years has found a subgroup of patients with a phenotype that resembles early T-cell precursor, which confers a much poorer prognosis than any other form of T-ALL. This novel subtype of T-ALL was called early T-cell precursor acute lymphoblastic leukemia (ETP-ALL). Flow cytometry data from T-ALL patients enrolled in Shanghai Children’s Medical Center between July 2002 and October 2010 were assessed according to Dr. Campana’s protocol. Among total 89 T-ALL cases, 74 cases had enough immunophenotype data available to differentiate between ETP (CD1a-, CD8-, CD5dim, at least one marker of stem cell or myeloid lineage) and non-ETP. From these 74 subjects, 12 ETP-ALL cases (16.2%) were identified. The event-free survival (EFS) rate at 66.8 months was 11.1%±10.1% for ETP-ALL and 57.6%±5.6% for non-ETP-ALL (P=0.003). The overall survival rates were 13.3%±11.0% for ETP-ALL and 64.7%±6.3% for non-ETP-ALL (P=0.002). Our findings demonstrate that early T-cell precursor leukemia is a very high-risk subtype of acute lymphoblastic leukemia with poor prognosis.
关键词: acute lymphoblastic leukemia early T precursor prognosis
A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma
Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang
《医学前沿(英文)》 2020年 第14卷 第6期 页码 711-725 doi: 10.1007/s11684-020-0808-3
关键词: chimeric antigen receptor T (CAR-T) cell lymphoma cytokine release syndrome (CRS) immune effector cell-associated neurotoxicity syndrome (ICANS)
Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection
Yun Tan, Feng Liu, Xiaoguang Xu, Yun Ling, Weijin Huang, Mingquan Guo, Ziyu Fu, Dongguo Liang, Miao Xu, Hongzhou Lu, Saijuan Chen
《医学前沿(英文)》 2020年 第14卷 第6期 页码 746-751 doi: 10.1007/s11684-020-0822-5
ZHU Lidong, CHEN Xiaoping
《医学前沿(英文)》 2007年 第1卷 第4期 页码 364-368 doi: 10.1007/s11684-007-0070-y
Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang
《医学前沿(英文)》 2020年 第14卷 第6期 页码 811-815 doi: 10.1007/s11684-020-0740-6
关键词: anti-CD19 chimeric antigen receptor T cells mantle cell lymphoma relapsed or refractory long-term follow-up
Precision medicine in acute lymphoblastic leukemia
Ching-Hon Pui
《医学前沿(英文)》 2020年 第14卷 第6期 页码 689-700 doi: 10.1007/s11684-020-0759-8
关键词: acute lymphoblastic leukemia molecular therapeutics targeted therapy tyrosine kinase inhibitors immunotherapy CAR T-cell therapy
Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition)
《医学前沿(英文)》 2022年 第16卷 第5期 页码 815-826 doi: 10.1007/s11684-021-0891-0
关键词: B-cell lymphoma oral drug targeted therapy immunotherapy COVID-19 pandemic
Paradoxical role of Id proteins in regulating tumorigenic potential of lymphoid cells
null
《医学前沿(英文)》 2018年 第12卷 第4期 页码 374-386 doi: 10.1007/s11684-018-0652-x
A family of transcription factors known as Id proteins, or inhibitor of DNA binding and differentiation, is capable of regulating cell proliferation, survival and differentiation, and is often upregulated in multiple types of tumors. Due to their ability to promote self-renewal, Id proteins have been considered as oncogenes, and potential therapeutic targets in cancer models. On the contrary, certain Id proteins are reported to act as tumor suppressors in the development of Burkitt’s lymphoma in humans, and hepatosplenic and innate-like T cell lymphomas in mice. The contexts and mechanisms by which Id proteins can serve in such contradictory roles to determine tumor outcomes are still not well understood. In this review, we explore the roles of Id proteins in lymphocyte development and tumorigenesis, particularly with respect to inhibition of their canonical DNA binding partners known as E proteins. Transcriptional regulation by E proteins, and their antagonism by Id proteins, act as gatekeepers to ensure appropriate lymphocyte development at key checkpoints. We re-examine the derailment of these regulatory mechanisms in lymphocytes that facilitate tumor development. These mechanistic insights can allow better appreciation of the context-dependent roles of Id proteins in cancers and improve considerations for therapy.
关键词: Id proteins lymphoma leukemia T cells B cells tumor suppressor oncogene
Deubiquitinases as pivotal regulators of T cell functions
null
《医学前沿(英文)》 2018年 第12卷 第4期 页码 451-462 doi: 10.1007/s11684-018-0651-y
T cells efficiently respond to foreign antigens to mediate immune responses against infections but are tolerant to self-tissues. Defect in T cell activation is associated with severe immune deficiencies, whereas aberrant T cell activation contributes to the pathogenesis of diverse autoimmune and inflammatory diseases. An emerging mechanism that regulates T cell activation and tolerance is ubiquitination, a reversible process of protein modification that is counter-regulated by ubiquitinating enzymes and deubiquitinases (DUBs). DUBs are isopeptidases that cleave polyubiquitin chains and remove ubiquitin from target proteins, thereby controlling the magnitude and duration of ubiquitin signaling. It is now well recognized that DUBs are crucial regulators of T cell responses and serve as potential therapeutic targets for manipulating immune responses in the treatment of immunological disorders and cancer. This review will discuss the recent progresses regarding the functions of DUBs in T cells.
关键词: deubiquitinase ubiquitination T cell activation T cell differentiation T cell tolerance
Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system
Xiaohui Wang, Zhiqiang Wu, Wei Qiu, Ping Chen, Xiang Xu, Weidong Han
《医学前沿(英文)》 2020年 第14卷 第6期 页码 726-745 doi: 10.1007/s11684-020-0746-0
关键词: CAR T cells immunoregulatory molecules endogenous immune response solid malignancies
Regulation of T cell immunity by cellular metabolism
null
《医学前沿(英文)》 2018年 第12卷 第4期 页码 463-472 doi: 10.1007/s11684-018-0668-2
T cells are an important adaptive immune response arm that mediates cell-mediated immunity. T cell metabolism plays a central role in T cell activation, proliferation, differentiation, and effector function. Specific metabolic programs are tightly controlled to mediate T cell immune responses, and alterations in T cell metabolism may result in many immunological disorders. In this review, we will summarize the main T cell metabolic pathways and the important factors participating in T cell metabolic programming during T cell homeostasis, differentiation, and function.
关键词: T cell immunity metabolic pathways nutrient uptake metabolic checkpoints
标题 作者 时间 类型 操作
Clinical characteristics and prognostic factors of patients with mature T-cell lymphoid malignancies:
null
期刊论文
intravenous busulfan conditioning with post-transplantation cyclophosphamide for allogeneic peripheral stem celltransplantation for adult patients with lymphoid malignancies: a prospective single-arm phase II study
Ling Wang, Lining Wang, Xing Fan, Wei Tang, Jiong Hu
期刊论文
Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia
null
期刊论文
A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma
Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang
期刊论文
Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection
Yun Tan, Feng Liu, Xiaoguang Xu, Yun Ling, Weijin Huang, Mingquan Guo, Ziyu Fu, Dongguo Liang, Miao Xu, Hongzhou Lu, Saijuan Chen
期刊论文
Change and significance of T-cell subsets and TNF-α in patients with advanced malignant obstructive jaundice
ZHU Lidong, CHEN Xiaoping
期刊论文
Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantlecell lymphoma
Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang
期刊论文
Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition)
期刊论文
Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system
Xiaohui Wang, Zhiqiang Wu, Wei Qiu, Ping Chen, Xiang Xu, Weidong Han
期刊论文